Annovis Bio logo

Annovis BioNYSE: ANVS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 January 2020

Next earnings report:

02 April 2025

Last dividends:

N/A

Next dividends:

N/A
$97.82 M
-55%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-55%vs. 3y high
94%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 28 min ago
$7.09+$0.59(+9.08%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ANVS Latest News

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs
globenewswire.com15 October 2024 Sentiment: POSITIVE

MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy.

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
globenewswire.com03 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition.”

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
globenewswire.com05 September 2024 Sentiment: POSITIVE

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative diseases, today announced that Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, held both virtually and in person at the Lotte New York Palace Hotel in New York City, September 9-11, 2024.

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
zacks.com03 July 2024 Sentiment: POSITIVE

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
investorplace.com02 July 2024 Sentiment: POSITIVE

Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson's, helping them retain and improve both motor and non-motor activities and cognitive functions.

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial
marketwatch.com02 July 2024 Sentiment: POSITIVE

Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.

Annovis Bio Files Patent for New Composition of Matter for Buntanetap
globenewswire.com26 June 2024 Sentiment: POSITIVE

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
globenewswire.com11 June 2024 Sentiment: POSITIVE

MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.

Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet
zacks.com28 May 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
businesswire.com16 May 2024 Sentiment: NEGATIVE

Glancy Prongay & Murray LLP, a prominent national law firm, has started investigating Annovis Bio, Inc. for potential breaches of federal securities laws. Investors who have incurred losses or are interested in exploring legal options under these laws are encouraged to contact the firm.

  • 1(current)

What type of business is Annovis Bio?

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

What sector is Annovis Bio in?

Annovis Bio is in the Healthcare sector

What industry is Annovis Bio in?

Annovis Bio is in the Biotechnology industry

What country is Annovis Bio from?

Annovis Bio is headquartered in United States

When did Annovis Bio go public?

Annovis Bio initial public offering (IPO) was on 29 January 2020

What is Annovis Bio website?

https://www.annovisbio.com

Is Annovis Bio in the S&P 500?

No, Annovis Bio is not included in the S&P 500 index

Is Annovis Bio in the NASDAQ 100?

No, Annovis Bio is not included in the NASDAQ 100 index

Is Annovis Bio in the Dow Jones?

No, Annovis Bio is not included in the Dow Jones index

When was Annovis Bio the previous earnings report?

No data

When does Annovis Bio earnings report?

The next expected earnings date for Annovis Bio is 02 April 2025